Abstract:Background: In the era of sentinel node biopsy (SNB), mainly aimed at local control, the axillary dissection (AD) was performed for breast cancer with positive node. It was argued that only level I/II lymph nodes dissection might be inadequate because nodes involvement was found in level III and interpectoral region when axillary node was positive. It is necessary to assess the extent of AD after modern preoperative axillary staging. The aim of this study was to investigate the incidence and associated factors of node involvement in level III/interpectoral region. Methods: A consecutive series of 338 core needle biopsy confirmed T0-2 invasive breast cancer cases were included in this study. Axillary node metastases were proved by ultrasound guided needle biopsy (NB) if ultrasonographic abnormal node was detected prior to SNB or by SNB if no abnormal node was detected. Cases of negative NB but positive SNB with image abnormal node were excluded. Prior to AD included level III and interpectoral lymph nodes, 4 to 8 cycles of neoadjuvant chemotherapy with anthrocyclin and/or taxane regimen were completed for each case. The chi-square test was used to determine the relation between level III/interpectoral lymph nodes metastases and clinicopathological factors. Multivariate logistic regression was analyzed for covariate selection. Results: A median of 19 axillary nodes was harvested per case (range: 5-46, average: 19.2). The pathologic complete response rate of axillary nodes was 35.3% (70/198) in NB positive subgroup. Level III and interpectoral lymph nodes were harvested in 76.9% (260/338) of cases (range: 1-8, average: 1.9, median: 1) and 49.7% (168/338) of cases (range: 1-10, average: 1.6, median: 1), respectively. The incidence of positive level III and interpectoral lymph nodes were 8.9% (30/338) and 8.9% (30/338), respectively. Node involvement of level III/interpectoral region was found in 13.3% (45/338) of these cases. The incidence of node involvement in level III/interpectoral region of NB positive subgroup (14.6%, 29/198) was not significantly higher compared with SNB positive subgroup (11.4%, 16/140, P=0.391). Increasing tumor size was significantly correlated with increasing likelihood of node involvement in level III/interpectoral region (T0-1: 6.3% vs T2: 16.7%, P=0.008). In SNB positive T0-1 subgroup, there was no positive node found in level III/interpectoral region. Multivariate analysis showed that tumor size was the only independent factors predicting node involvement in level III/interpectoral region (OR=3.488, 95%CI:1.427-8.528, P=0.006). Conclusions: The incidence of node involvement in level III/interpectoral region was 13.3% of nodes positive T0-2 breast cancer treated with neoadjuvant chemotherapy. Tumor size may be the predictor of node involvement in this region. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-01-27.

Analysis on Axillary Lymph Node Metastasis of Different Groups of Breast Cancer Patients

High Risk For Non-Sentinel Node Metastasis In Breast Cancer Patients With Sentinel Node Metastases

Role of Number of Sentinel Nodes in Predicting Non-Sentinel Node Metastasis in Breast Cancer

Incidence and Risk Factors of Lymph Node Metastasis in Breast Cancer Patients Without Preoperative Chemoradiotherapy and Neoadjuvant Therapy: Analysis of SEER Data.

Exploration of the Extent of Axillary Dissection for Patients with Node Positive Primary Breast Cancer

Research progress of axillary management approach for 1-2 sentinel lymph node positive early stage breast cancer patients

Can Axillary Lymph Node Dissection be Omitted in Breast Cancer Patients with Metastatic Sentinel Lymph Nodes Undergoing Mastectomy? A Systematic Review and Meta-Analysis of Real-World Evidence

Positive metastasis axillary lymph nodes after radical mastectomy for breast cancer as an indication of postoperative radiotherapy

Lymph Node Counts and Ratio in Axillary Dissections Following Neoadjuvant Chemotherapy for Breast Cancer: A Better Alternative to Traditional Pn Staging

Abstract P1-01-27: Level III and Interpectoral Lymph Nodes Involvement in Breast Cancer with Positive Axillary Lymph Nodes after Neoadjuvant Chemotherapy

The pattern of lymph node metastasis in peripheral pulmonary nodules patients and risk prediction models

Progress and strategy for axillary management of breast cancer

Management Strategy of Early-Stage Breast Cancer Patients with a Positive Sentinel Lymph Node: with or Without Axillary Lymph Node Dissection

Clinical research in endoscopically axillary sentinel lymph node biopsy for breast cancer

An analysis of the incidental irradiation to the axillary levelsⅠ-Ⅲlymph node during radiotherapy after breast conserving surgery

Modified radical mastectomy for level III axillary lymph node clearance: a case report

Axillary Lymph Node Dissection in Triple-Negative or HER2-positive Breast Cancer Patients with Clinical N2 Achieving Pathological Complete Response after Neoadjuvant Therapy: is It Necessary?

Axillary management in patients with clinical node-negative early breast cancer and positive sentinel lymph node: a systematic review and meta-analysis

Correlation Analysis of Pathological Features and Axillary Lymph Node Metastasis in Patients with Invasive Breast Cancer

An exploratory study of whether axillary lymph node dissection can be avoided in breast cancer patients with positive lymph nodes

The feasibility of targeted axillary dissection for breast cancer axillary surgery de-escalation after neoadjuvant therapy: A prospective cohort study